Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration

Randall D. Marshall, Abigail Collins, Maria L. Escolar, H. A. Jinnah, Thomas Klopstock, Michael C. Kruer, Aleksandar Videnovic, Amy Robichaux-Viehoever, Colleen Burns, Laura L. Swett, Dennis A. Revicki, Randall H. Bender, William R. Lenderking

Research output: Contribution to journalArticle

Abstract

Background: Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal recessive neurodegenerative disorder with brain iron accumulation (NBIA). Objectives: To assess PKAN diagnostic pathway, history, and burden across the spectrum of PKAN severity from patient and/or caregiver perspectives. Methods: Caregivers of patients (n = 37) and patients themselves (n = 2) were interviewed in a validation study of the PKAN-Activities of Daily Living (ADL) scale. The current study used quartiles of the PKAN-ADL total score to divide patients by severity of impairment (Lowest, Second Lowest, Third Lowest, Highest). Diagnostic and treatment history, healthcare utilization, disease burden, and caregiver experience were compared between groups. Results: The analyses included data from 39 patients. Mean age at PKAN symptom onset (P = 0.0007), initial MRI (P = 0.0150), and genetic testing (P = 0.0016) generally decreased across the PKAN severity spectrum. The mean duration of illness did not differ among PKAN severity groups (range, 9.7-15.2 years; P = 0.3029). First MRI led to diagnosis in 56.4% of patients (range, 30.0-90.0%). A mean (SD) of 13.0 (13.1) medical and 55.2 (78.5) therapy visits (eg, physical, speech) occurred in the past year. More patients in the higher PKAN severity groups experienced multiple current functional losses and/or earlier onset of problems (P-values < 0.0500). Over half (56.8%) of caregivers experienced a change in employment because of caregiving. The percentage of patients requiring full-time caregiving increased across the PKAN severity spectrum (range, 11.1-100%; P = 0.0021). Conclusions: PKAN diagnosis was often delayed, most probably due to low awareness. Considerable burden of functional impairment and high healthcare utilization were found across the PKAN severity spectrum.

Original languageEnglish
Article number174
JournalOrphanet Journal of Rare Diseases
Volume14
Issue number1
DOIs
StatePublished - Jul 12 2019

Keywords

  • Burden of illness
  • Caregiver
  • Healthcare utilization
  • PKAN
  • PKAN-ADL scale

Fingerprint Dive into the research topics of 'Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration'. Together they form a unique fingerprint.

  • Cite this

    Marshall, R. D., Collins, A., Escolar, M. L., Jinnah, H. A., Klopstock, T., Kruer, M. C., Videnovic, A., Robichaux-Viehoever, A., Burns, C., Swett, L. L., Revicki, D. A., Bender, R. H., & Lenderking, W. R. (2019). Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration. Orphanet Journal of Rare Diseases, 14(1), [174]. https://doi.org/10.1186/s13023-019-1142-1